

Role of Bacteriocin in Tackling the Global Problem of Multi-Drug Resistance: An Updated Review

K.L.R. Bonhi and Sabiha Imran*

Department of Biotechnology, Faculty of Engineering and Technology, Manav Rachna International Institute of Research and Studies, Sector 43, Faridabad, Haryana 121004, India

ABSTRACT

Bacterial resistance to antimicrobials has reached an unacceptable level which threatens the very existence of man and animal alike if the situation is not corrected in the near future. The development of novel antibiotics is a slow time consuming process which leaves us with inadequate means to control microbial infections. It is imperative that we adopt alternative therapeutic strategies to ensure removal of resistant micro-organisms from our living space. Bacteriocins are powerful bactericidal peptides produced and secreted by a varied group of micro-organisms including yeast, protozoa and of course bacteria and they cause death and removal of non bacteriocin producing pathogenic bacteria. These bacteriocin treatments offer more benefits over antibiotic therapies in present time as they are natural bioactive peptides having no side effects. This paper is a review of MDR (Multiple Drug Resistance) related issues which have become a global problem and on the possible role of bacteriocins as an effective option for fighting against MDR disease causing bacteria. The potential of Bacteriocins as an alternate or adjuvant to antibiotics needs to be studied and made available to the medical community. Recent trends suggest that if an effective alternate to antibiotics is not found quickly then the very existence of mankind could come under threat. The safety profile of bacteriocins is much superior to antibiotics. This is another important reason to study bacteriocins and tap their therapeutic potential to combat drug resistant bacterial infections.

KEY WORDS: ALTERNATIVE THERAPEUTIC STRATEGY, ANTIMICROBIALS, BACTERIOCINS, GLOBAL PROBLEM, MULTI-DRUG RESISTANCE

ARTICLE INFORMATION:

Corresponding Author: sabiha.fet@mriu.edu.in

Received 1st Aug, 2019

Accepted after revision 24th Sep, 2019

BBRC Print ISSN: 0974-6455

Online ISSN: 2321-4007 CODEN: USA BBRCBA

Thomson Reuters ISI ESC / Clarivate Analytics USA



Crossref

Clarivate
Analytics

NAAS Journal Score 2019: 4.31 SJIF: 4.196

© A Society of Science and Nature Publication, Bhopal India

2019. All rights reserved.

Online Contents Available at: <http://www.bbrc.in/>

DOI: 10.21786/bbrc/12.3/8

INTRODUCTION

Microorganism impervious to antibiotic treatment have become wide spread which is a global phenomena needs to be controlled before it becomes a unmanageable deadly threat to the health and wellbeing of human life. The phenomena of antibiotic resistance can be attributed to inappropriate, self medication and excessive prescription of antibiotics over the past several years all over the world according to Carlet et al (2012). Development of reasonable alternatives to antibiotics are in need to get universal public health out of danger (Carlet et al., 2012 Oldfield and Feng, 2014 and WHO, 2015). Antimicrobials used in food industries, bio-preservatives or antibacterial peptides like Nisins, pediocin, mersacidin, mutacin and lactacin have proved to be active against Vancomycin Resistant Enterococci and Methicillin Resistant Staphylococcus aureus strains, have instance of potential therapeutic strategy to kill bacterial infections and multidrug-resistant bacteria (Papagianni and Anastasiadou, 2009, Nishie et al., 2012, Bodaszewska-Lubas et al., 2012, Lohans and Vederas 2012, Laxminarayan et al., 2016, Santos et al., 2017, Delpech 2017, Mathur, et al., 2018).

The bacteriocins are very small ribosomally synthesized peptide molecules secreted by archea, gram-positive and some of gram-negative bacteria (Klaenhammer et al., 1988 and Zheng, et al., 2015) as well as synthesized by ribosomes with antimicrobial properties against various groups of microorganisms (Chikindas, et a., 2017). The activity of bacteriocins is influenced by temperature, pH, and composition of culture medium (Guinane et al., 2015 and Turgis, et al., 2016). The bacteriocins were first described in 1925, however their production, functions and applications in medical field has been explored in recent times (Chikindas, et al., 2017). Recently, it has been defined that bacteriocins are secreted not only by bacteria but also by others like yeast and mould, virus, eukaryotic cells like sperm cell, cancer cell and also from protozoans (Drider et al., 2016, Jiang, et al., 2016, Chikindas et al., 2017, Mills et al., 2017, Diep, et al., 2018, Lopetuso, et al., 2019).

Bacteriocin has already found commercial application in food preservation and dairy farming therefore it is not far-fetched to assume that Bacteriocins will soon be available for the benefit of humans also this may be as a therapeutic agent against MDR bacteria. They are being investigated as a potential alternative or adjuvant in combination with antibiotics to combat disease causing pathogens. The fact that they have an excellent safety and resistant profile is an added incentive towards studying them. They are considered as therapeutic complements despite therapeutic alternative to chemical antibiotics as they have high stability and very low toxicity.

Advantages of Bacteriocin Treatment over Antibiotic Therapy

Antibiotics are a group of pharmaceuticals that play a vital role in keeping both humans and animals disease free thus having an important influence on the quality of life of an individual (Stepanauskas, 2006). Antibiotic resistance is a growing threat to the efficacy of these agents and has serious consequences in terms of morbidity and mortality of those undergoing treatment (Fair, et al., 2014). Due to the development and dispersal of antibiotic resistance and their several side effects, treatment with antimicrobial peptides is a needed requirement (Chen et al., 2012). Bacteriocins are bacterial extracellular ribosomal integrated peptides or proteins having antibacterial action against closely related microbial species (Tashakor et al., 2017, Castro et al., 2011, Opsata et al., 2010, Morisset and Frère 2002). Bacteriocins influence the immune system and inhibit competitive strains by directly influencing the niche competition among commensals (Kommineni, et al., 2015). The bacteriocin A or bacteriocin 21 produced by Enterococcus faecalis can eradicate multidrug resistant bacteria and contribute to regulation of niche competition among intestinal bacteria (Kommineni, et al., 2015). Likewise, LAB bacteriocins play role against Staphylococcus aureus (Umu, et al., 2017), some vancomycin resistant enterococci (Kommineni, et al., 2015), Salmonella enteritidis (Umu, et al., 2017), Clostridium difficile (Rea, et al., 2013) and Listeria monocytogenes (Umu, et al., 2017). Additional investigations are required to test the therapeutic potential of above outcomes. The antibacterial properties of bacteriocins are exploited by applications in food technological research. In particular, bacteriocins are used as food preservatives (Oldak, et al., 2017) and preservation of dairy products (Linares, et al., 2017) with categorization such as partially purified bacteriocins, crude-fermented dairy bacteriocins and protective cultures bacteriocins (Henning, et al., 2015, Anacarso, et al., 2017, Chikindas, et al., 2017, Ahmad, et al., 2017, Hammami, et al., 2019).

Mode of Action of Bacteriocin

Most of the bacteriocins can inhibit growth of pathogens in order to defend their producer and play a role in signalling peptides (Hegarty, et al., 2016). They can act as pore-forming agents or membrane perturbers (Etayash et al 2015) or interfere with the cell division processes. The bacteriocins possess antiviral, spermicidal (Chikindas, et a., 2017), anticancer properties (Kaur et al 2015) and capable of enhancing the positive effects of probiotic bacteria as seen in the Bifidobacterium strain (Weinstock, et al., 2016 and Hegarty, et al., 2016).

Different viewpoints distinguish bacteriocins from antimicrobial drugs: (i) Bacteriocins are synthesized on

the ribosomal surface in bacterial cells, while antibiotics are bacterial secondary metabolite; (ii) Antibiotic producers are easily affected by antimicrobial agents whereas the producers of bacteriocin are not susceptible to antimicrobial agents; (iii) Bacteriocins can get fixed to the target bacterial cell surface anywhere because target bacterial cell surface doesn't possess any specific receptors; (iv) Bacteriocins get attached to the target cell wall surface and form pore in the outer membrane surface because of ionic imbalances (Morisset and Frère, 2002) another side chemical antimicrobials are responsible for disruption of cell wall (bacterial) synthesis, formation of genomic protein and replication processes (Svetoch et al., 2011, Cotter et al., 2013, da Silva Sabo et al., 2014, Woraprayote et al., 2016, and Perez et al., 2018).

Emergence of Bacterial Resistance to Antibiotic

The resistant bacterial microorganisms are acquired by human being through consumption of animal meat. These bacteria show changes at the gene level which plays a role in them acquiring resistance to antibiotics. Consequently the consumer of such meat becomes insensitive to the action of antibiotics involved (Ventola, 2015, Holmes, et al., 2016, Chakchouk-mtibaa, et al., 2017, Vijayakumar and Muriana, 2017, Costa, et al., 2019).

Bacterial resistance emerges and propagates due to the reasons listed below:

1. Excessive consumption of antibiotics: Over utilization of antibiotics leads to multiple drug resistance which invariably selects the resistant species of normal flora. The excessive utility of those medicines might be due to lack of information or overzealous and sometimes even profit driven treatment for various viral and bacterial infections (Nitsch-Osuch et al., 2016).
2. Overprescribing of antibiotics: Apart from excessive consumption, the number of inappropriate prescriptions of antimicrobial agents is also shocking. It has been found that there are errors of about 30 - 50 % in terms of choice and duration for which the antibiotics need to be consumed (Ventola, 2015). It has been observed that the sub therapeutic doses of antibiotics promote bacterial phenotypical variations and resistance to bacterial infections builds up (Viswanathan, 2014).
3. Antibiotic use in agronomy as well as animal husbandry: It was observed that in 2011 in the US, the use of antimicrobials as a growth enhancer in livestock was approximately 13,000 tons. That year more than 42,000,000 tons meat was produced which was an average of at least 320 mg of the bactericidal per kilogram of meat (Aarestrup, 2015).

Research Regarding Bacteriocin's Effect on Multi Drug Resistance Bacteria

Researchers from Howard University Washington DC have shown that probiotic isolate from yogurt has strong antimicrobial activity. Among the multiple *Lactobacillus* isolated and studied one particular isolate *Lactobacillus parafarraginis*, was reported to be sensitive against fourteen multi drug resistant bacteria (Allen-McFarlane et al., 2019).

Recently, the bacteriocins from *Vibrio*, *Aeromonas*, *Pseudoal-teromonas* and *Alteromonas* were sourced from the ocean and were noted to have high bactericidal activity. They provide defence system against multidrug-resistant bacteria by establishing bacteriocins. The system is found to be reasonable alternatives to antibiotics for high biodiversity of the ecosystem (Desriac et al., 2010).

On the contrary, Sachsenrödder et al. (2014) postulated that the administration of probiotics (bacteriocins from *Enterococcus faecium*) to diarrhoea causing virus in pig gut would be therapeutic but they failed to prove the same through actual results (Sachsenrödder et al., 2014). Previous study also showed that pyocin, a bacteriocin produced by *Pseudomonas aeruginosa* were not able to treat pulmonary disease caused by pseudomonas in patients (Ghoul et al., 2015) Bacteriocin isolated from *Bacillus subtilis* that have been used to increase shelf life of food items have showed activity against only a very few gram positive bacteria like *S. epidermidis*. They failed to show activity against any drug-resistant bacteria (Sharma et al., 2018) Studies have been also conducted on AS 48 and nisin, a bacteriocin from *Lactococcus lactis* with AS48 being effectively bactericidal against *Staphylococcus* in cereal drink only when those are combined with phenol compounds (Antonio, et al., 2019).

Researchers from Leuven Belgium have studied the mode of action of LipA bacteriocin which helps to kill multidrug-resistant *Pseudomonas aeruginosa*. Their work has shown that the bacteriocin is both effective and very specific in targeting the pathogenic organism (Martín-Escolano, et al., 2019). Perales-Adán J, et al (2018) had shown the bactericidal action of bacteriocins (AS-48 and nisin) against drug-resistant *Staphylococcus aureus* present in goat milk cheese both individually and in combination. The combined action of these bacteriocins is even more effective because of synergy (Perales-Adán, et al. 2018). Scientists from Pakistan have studied the BAC-IB-17 bacteriocin produced by *Bacillus subtilis* and was found it to be effective against MRSA. This bacteriocin was highly thermo stable and therefore would retain its activity in a range of extreme environments (Ansari, et al., 2018).

Indian researchers from CSIR- Institute of Microbial Technology, Chandigarh, have shown that the bacteri-

ocin 'Sonorensin' is effective against antibiotic-resistant *Staphylococcus aureus* biofilms and other bacteria of gram- positive and gram- negative types (Chopra, et al., 2015).

Five antimicrobial peptides are designed by Indian Institute of Science, Bangalore scientists. The peptide $\Omega 76$ which is among the five peptides was effective against carbapenem and tigecycline-resistant *Acinetobacter baumannii* in mice. The peptides are nephrotoxic lead to side effects in patients which may be treated with conventional antibiotics (Nagarajan, et al., 2019). A scientists' team from China studied antimicrobial peptide Cec4 for its structure and mode of action. The peptide is effective against the drug-resistant nosocomial infections caused by *A. baumannii* (Peng, et al., 2019).

A team of scientists at MIT has discovered a peptide from the venom of a South American wasp. They successfully developed and refined several variants of this peptide and tested their efficacy in mice infected with Antibiotic-resistant *Pseudomonas aeruginosa*. Among all the peptides tested one peptide was seen to eradicate the infection- an encouraging and interesting result (Marcelo, et al. 2018). The bactericidal actions of bacteriocins were studied VidhyaPrakash et al. which were produced by *L. fermentum* and *L. casei* 335 showed effective against antibiotic-resistant *Escherichia coli* and also drug resistant *Salmonella typhi* bacteria. This study showed that both the pathogenic bacteria were inhibited by bacteriocin action (Prakash, et al. 2018). Also in our research we have found a bacteriocin producing lactobacillus which is very much effective against Methicillin resistant *Staphylococcus aureus* (Bonhi and Imran, 2019).

MDR Bacteria and Antibiotic Resistance - The Global Scenario

According to report published by UN in April 2019, there may be loss of lives every year numbering up to 1,00,00,000 caused by drug resistant diseases by 2050. The causality may be similar to disastrous economic loss during 2008-09. Antimicrobial resistance may lead to 24 million into extreme poverty by 2030. Drug resistant infections lead to death of minimum of 7,00,000 individuals every year. Tubercle bacilli multidrug-resistant infection lead to death of 2,30,000 additionally. Sexually transmitted infections, Urinary tract infections and common respiratory tract infections are untreatable in present context. The treatments meant for life saving became risky and modern food systems are increasingly uncertain (Chaib, et al. 2019).

The prevalence of carbapenems degrading enzymes New-DelhiMetallo-beta - lactamase-1 and *Klebsiella pneumoniae* carbapenemase-2 are matter of concern to the researchers for treatment of infectious diseases

due to inadequacy of antibiotics (Liu et al., 2016). The "One Health" approach of UN recommends countries to redress antimicrobial resistance and to ensure efficacy for essential medicines by framing strategic plan for deployment activities like finance and arranging awareness programs for prudent use of antimicrobials. It insists to invest in research and development for new technologies to combat antimicrobial resistance and growth of critically essential antimicrobials in agriculture (Chaib, et al. 2019).

MDR Bacteria and Antibiotic Resistance - The Indian Scenario

The problem of Antibiotic resistance has assumed serious proportions in India too. Findings from a study published by ICMR show the presence of antibiotic resistant bacteria in the digestive system of 2 out of every 3 individuals tested thus confirming the high prevalence and spread of Antibiotic resistance in Indian population. The resistance was more for frequently used antibiotics like cephalosporins (60 %) and fluoroquinolones (40%). This study is a wakeup call for the future because a similar resistance for higher end antibiotics would be disastrous. Of even more concern is the threat of Drug resistant tuberculosis. The Central TB division is found with declaration furnished in 2018 by Ministry, Health and Family Welfare. As per the declaration, there were approximately 2.8 million new cases of TB every year and 1,47,000 new cases of drug resistant TB. There were 87,000 new cases of HIV-TB every year and deaths due to TB excluding HIV was 4, 23,000 which is alarm for immediate effective action. The Indian government has resolved to eliminate TB by 2025. Consequently, Indian Council of Medical Research (ICMR) launched nation's first wide-scale trial for two newly invented vaccines of tuberculosis (TB) on 15/7/ 2019 to facilitate prevention in spread of Drug resistant TB (Mascarenhas, 2019). NDM-1 (New-Delhi Metallo-beta - lactamase-1) is a gene produced by bacterial microorganisms which makes the concerned bacterium multi drug resistant. This gene produces an enzyme which makes the antibiotics resistant. This Gene has originated in India and was first detected in a Swedish patient who had visited India for a surgery in the year 2008. There after this resistant bacteria (*Klebsiella pneumoniae*) having MDR-1 gene had spread all over India and across 70 different countries all over the world. The Indian government had taken various measures to tackle this situation and also focused on improving sanitation and providing clean and healthy water. These measures in public health will definitely help in reducing microbial resistance (Aggarwal, 2019).

The Indian government had also taken strict action in August 2019 to combat the menace of MDR. Notable among them is the ban on colistin, one of the last resort

antibiotics for human infectious diseases. This ban is not only on use of colistin as a growth promoter but also on its manufacture, sale and distribution because the consumption of such food product whether meat or poultry would expose the Indian population on the risk of MDR (Ghafur, 2019).

Future Perspectives

Bacteriocins are already being used commercially for food preservation and as a probiotic but their use as a therapeutic agent against human diseases still in the development stage and a reason for much excitement in the scientific and medical community alike. A massive and sustained effort is required to achieve this goal to combat the threat of MDR in shortest possible period of time. Scientists from different parts of the world are trying to isolate a broad spectrum anti - pathogenic bacteriocin which could be as effective as antibiotic therapy and have a lot of untapped potential as therapeutic agents. A cocktail of bacteriocins with differing spectrum of action could be as effective as a broad spectrum antibiotic. Bacteriocins could be combined with an antibiotic without compromising on the efficacy but reducing the unwanted side effects of antibiotic therapy. This would also help prevent development of both antibiotic resistance and bacteriocin resistant microbes. The pairs or group of bacteriocins showing augmented bactericidal action when working together as compared to when they act alone is another property being looked for (Antonio et al., 2019). The future prospects for bacteriocins as therapeutic agents have lots of potential as shown promising activity against biofilms (Kim et al., 2019). Experts have estimated that by the year 2060 more than 20 new classes of antibiotics would be needed to cope-up with the challenge posed by antibiotic resistance (Li et al., 2018). Only A few antimicrobial peptides are approved so far by FDA and EMEA (Cattoir et al., 2019). The pharma industry is reluctant to support research activities of bacteriocins due to high production cost. With commercialization of bacteriocin based products and improved low cost production techniques coupled with increase in demand with time it is estimated that the cost to the consumer will go down significantly.

CONCLUSION

The human population is heading towards disaster unless antibiotics with broader antimicrobial activity are developed soon. There may be a number of unpublished antibiotics which are in preclinical stage of development. Approval process for newly developed drugs that include bacteriocins and antimicrobial peptides by medical control councils has been slow due to several safety and clinical tests which involve analysis of

resistance to antimicrobial activity, allergies and effect on immune system of hosts. Bacteriocins can be used for prevention of infections, to fight against antibiotic resistance and treatment owing to their diversity and abundance. Bacteriocins are an interesting option being studied for future use as a therapeutic option against multi drug resistant bacteria. Much more research is required towards development of novel effective bacteriocins which successfully target complex bacterial systems such as cell membranes.

REFERENCES

- Aarestrup F. M., Agerso Y., Gerner-Smidt P., Madsen M. and Jensen L.B. (2000) Comparison of antimicrobial resistance phenotypes and resistance genes in *Enterococcus faecalis* and *Enterococcus faecium* from humans in the community, broilers, and pigs in Denmark. *Diagn. Microbiol. Infect. Dis.* Vol. 37 No. 2 : Pages 127-137.
- Aggarwal A. (2019) India, the antibiotic capital of the world. <https://www.downtoearth.org.in/blog/health/india-the-antibiotic-capital-of-the-world-63097>.
- Ahmad V., Khan M. S., Jamal Q. M. S., Alzohairy M. A., Al Karaawi M. A. and Siddiqui M. U. preservation. *International Journal of Antimicrobial Agents* . Vol. 49 No. 1 : Pages 1-11.
- Anacarsio I., Gigli L. and Bondi M. (2017) Isolation of two *lactobacilli*, producers of two new bacteriocin-like substances (BLS) for potential food-preservative use. *European Food Research and Technology*. Vol. 243 No. 12: Pages 2127-2134
- Ansari A., Zohra R. R., Tarar O. M., Qader S. A. U., Aman A. (2018) Screening, purification and characterization of thermostable, protease resistant Bacteriocin active against methicillin resistant *Staphylococcus aureus* (MRSA). *BMC Microbiol.* vol.18 No.1 pages 1-10.
- Antonio C. M., Abriouel H., Jaén U., López R. U. and Bakali N. B. E. (2019) Enhanced bactericidal activity of enterocin AS-48 in combination with essential oils, natural bioactive compounds and chemical preservatives against *Listeria monocytogenes* in ready-to-eat salad. *Food and chemical toxicology*. Vol. 47 No. 9 : Pages 2216-23
- Allen-McFarlane R., Douglas Allen A., Bansal G. and Eribo, B., (2019) Isolation And Characterization of L. Parafarraginis (Ku495926) Inhibiting Multidrug-Resistant And Extended Spectrum Beta-Lactamase Gram-Negative Bacteria. *J Microbiol Biotech Food Sci*. Vol. 8 No 4 pages : 1041-1053.
- Bonhi K. L. R. and Imran S. (2019) Efficacy Evaluation and Partial Characterization of Methicillin Resistant *Staphylococcus aureus* (MRSA) Sensitive Bacteriocin Producing *Lactobacillus*. *International Journal of Basic and Applied Biology* Vol. 6 No. 1: Pages 15 - 17.
- Bodaszewska-Lubas M., Brzywczy-Wloch M., Gosiewski T. and Heczko P.B. (2012) Antibacterial activity of selected standard strains of lactic acid bacteria producing bacteriocins pilot study. *Postepy Hig. Med. Dosw.* Vol. 66: Pages 787-794.

- Carlet J., Rambaud C. and Pulcini C., (2012) WAAR (World Alliance against Antibiotic Resistance): safeguarding antibiotics. *Antimicrob. Resist. Infect. Control* Vol.1 No.1 : Pages 25–30.
- Castro M. P., Palavecino N. Z. P., Herman C. H., Garro O. A. G. and Campos C. A. C. (2011) Lactic acid bacteria isolated from artisanal dry sausages: Characterization of antibacterial compounds and study of the factors affecting bacteriocin production. *Meat Science* Vol. 87: Pages 321–329.
- Cattoir V, and Felden B. (2019) Future Antibacterial Strategies: From Basic Concepts to Clinical Challenges. *The Journal of Infectious Diseases*. Vol. 220 No. 3: Pages 350–360.
- Chaib F., John B. and Hwang S. (2019) New report calls for urgent action to avert antimicrobial resistance crisis. Joint News Release, New York.
- Chakchouk-mtibaa A., Smaoui S. and Ktari N. (2017) Biopreservative efficacy of bacteriocin BacFL31 in raw ground Turkey meat in terms of microbiological, physicochemical, and sensory qualities. *Biocontrol Science*. Vol. 22 No. 2 : Pages 67–77.
- Chen Z., Yang X., Liu Z., Zeng L., Lee W. and Zhang Y. (2012) Two novel families of antimicrobial peptides from skin secretions of the Chinese torrent frog, *Amolopsjingdongensis*. *Biochimie* Vol. 94 No. 2 : Pages 328–334.
- Chikindas M. L., Weeks R., Drider D., Chistyakov V. A. and Dicks L. M. (2017) Functions and emerging applications of bacteriocins. *Curr.Opin.Biotechnol.* Vol. 49: Pages 23–28.
- Chopra L., Singh G., Jena K. K. and Sahoo D. K. (2019) Sonorinsin: A new bacteriocin with potential of an anti-biofilm agent and a food biopreservative. *Scientific Reports* Vol. 5 pages 1 – 13.
- Costa R. J. D., Voloski F. L. S., Mondadori R. G., Duval E. H. and Fiorentini A. M. (2019) Preservation of Meat Products with Bacteriocins Produced by Lactic Acid Bacteria Isolated from Meat. *Journal of Food Quality*. Vol. 2019: Pages 1-12
- Cotter P. D., Ross R. P., and Hill C. (2013). Bacteriocins - a viable alternative to antibiotics? *Nat. Rev. Microbiol.* Vol. 11: Pages 95–105.
- Da Silva Sabo S., Vitolo M., González J. M. D., and De Souza Oliveira R. P. (2014). Overview of *Lactobacillus plantarum* as a promising bacteriocin producer among lactic acid bacteria. *Food Res. Int.* Vol. 64 : Pages 527–536.
- Delpech P., Rifa E., Ball G., Nidelet S., Dubois E. and Gagne G. (2017) New insights into the anti-pathogenic potential of *Lactococcus garvieae* against *Staphylococcus aureus* based on RNA sequencing profiling. *Front. Microbiol.* Vol. 8:359.
- Diep D. B., Telke A. A., Ovchinnikov K. V., Vuoristo K., Mathiesen G., and Thorstensen T. (2018) Over 2000-fold increased production of the leaderless bacteriocin garvicin KS by genetic engineering and optimization of culture conditions. *bioRxiv*.
- Desriac F., Defer D., Bourgougnon N., Brillet B., Le Chevalier P. and Fleury Y. (2010) Bacteriocin as weapons in the marine animal-associated bacteria warfare: inventory and potential applications as an aquaculture probiotic. *Mar. Drugs* Vol. 8 No. 4 : Pages 1153–1177.
- Drider D., Bendali F., Naghmouchi K. and Chikindas M. (2016) Bacteriocins: not only antimicrobial agents. *Probiotics Antimicrob. Proteins* Vol. 8 : Pages 177–182.
- Etayash H., Azmi S., Dangeti R. and Kaur K. (2015) Peptide Bacteriocins–Structure Activity Relationships. *Curr.Top. Med. Chem.* Vol. 16: Pages 220–241.
- Fair R. J. and Tor Y. (2014) Antibiotics and bacterial resistance in the 21st century. *Perspect. Med. Chem.* Vol. 6: Pages 25–64.
- Ghafur A. (2019) India now takes antibiotic resistance more seriously than it did a decade ago ... We must promote good hygiene practice <https://timesofindia.indiatimes.com/blogs/the-interviews-blog/india-now-takes-antibiotic-resistance-more-seriously-than-it-did-a-decade-ago-we-must-promote-good-hygiene-practice/>
- Ghoul M., West S. A., Johansen H. K., Molin S., Harrison O. B., Maiden M. C., Jelsbak L., Bruce J. B. and Griffin, A. S. (2015) Bacteriocin-mediated competition in cystic fibrosis lung infections. *Proc. Biol. Sci.* Vol. 282.
- Guinane C. M., Piper C., Draper L. A., O'Connor P. M., Hill C., Ross R. P. and Cotter P. D. (2015) Impact of Environmental Factors on Bacteriocin Promoter Activity in Gut-Derived *Lactobacillus salivarius*. *Appl. Environ. Microbiol.* Vol. 81: Pages 7851–7859.
- Hammami R., Fliss I., and Corsetti A. (2019) Editorial: Application of Protective Cultures and Bacteriocins for Food Biopreservation. *Frontiers in Microbiology*. Vol. 10 : Pages 1-2.
- Hegarty J. W., Guinane C. M., Ross R. P., Hill C. and Cotter, P. D. (2016) Bacteriocin production: A relatively unharnessed probiotic trait? Vol. 5: Page 2587.
- Henning C., Vijayakumar P., Adhikari R., Jagannathan B., Gautam D. and Muriana P. M. (2015) Isolation and taxonomic identity of bacteriocin producing lactic acid bacteria from retail foods and animal sources. *Microorganisms*. Vol. 3: Pages 80–93.
- Holmes P., and Mauer J. (2016). Antimicrobial resistance and new antibiotics. *Health Aff.* Vol. 35:1935.
- Jiang H., Li P., and Gu Q. (2016). Heterologous expression and purification of plantaricin NC8, a two-peptide bacteriocin against *Salmonella* spp. from *Lactobacillus plantarum* ZJ316. *Protein Expr. Purif.* Vol.127: Pages 28–34.
- Kaur S. and Kaur S. (2015) Bacteriocins as Potential Anticancer Agents. *Front. Pharmacol.* Vol. 6: Pages 272.
- Kommineni S., Bretl D. J., Lam V., Chakraborty R., Hayward M., Simpson P., Cao Y., Bousounis P., Kristich C. J. and Salzman N. H. (2015) Bacteriocin production augments niche competition by enterococci in the mammalian gastrointestinal tract. Vol. 526: Pages 719–722.
- Kim Na N., Kim June W. and Kang Seong S. (2019) Anti-biofilm effect of crude bacteriocin derived from *Lactobacillus brevis* DF01 on *Escherichia coli* and *Salmonella Typhimurium*. *Food control.* Vol. 98: Pages 274–280.
- Klaenhammer T. R. (1988) Bacteriocins of lactic acid bacteria. *Biochimie* Vol. 70: Pages 337–349.

- Laxminarayan R., Matsoso P., Pant S., Brower, C., Rottingen J. A., Klugman K., et al. (2016). Access to effective antimicrobials: a worldwide challenge. *Lancet*. Vol. 387 : Pages 168–175.
- Li B. and Webster T. J. (2018) Bacteria Antibiotic Resistance: New Challenges and Opportunities for Implant-Associated Orthopaedic Infections. *J Orthop Res*. Vol. 36 No. 1: Pages 22–32.
- Linares D.M., Gomez C., Renes E., Fresno J.M., Tornadijo M.E., Ross R.P. and Stanton C. (2017) Lactic Acid Bacteria and Bifidobacteria with Potential to Design Natural Biofunctional Health-Promoting Dairy Foods. *Front. Microbiol*. Vol. 8: Pages 846.
- Liu Y. Y., Wang Y., Walsh T. R., Yi L.X., Zhang R., Spencer J., Doi Y., Tian G., Dong B., Huang X., Yu L. F., Gu D., Ren H., Chen X., Lv L., He D., Zhou H., Liang Z., Liu J. H. and Shen, J. (2016) Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect. Dis*. Vol.16 No. 2 : Pages 161–168.
- Lohans C. T. and Vederas J. C. (2012) Development of class II bacteriocins as therapeutic agents. *Int. J. Microbiol*. Vol. 201: 386410.
- Lopetuso L. R., Giorgio M. E., Saviano A., Scaldaferrri F., Gasbarrini A., and Cammarota G. (2019) Bacteriocins and Bacteriophages: Therapeutic Weapons for Gastrointestinal Diseases? *Int J Mol Sci*. Vol. 20 No. 1: Pages 1 - 12.
- Marcelo D. T. T., Pedron C. N. and Higashikuni Y. (2018) Structure-function-guided exploration of the antimicrobial peptide polybia-CP identifies activity determinants and generates synthetic therapeutic candidates. *Communications Biology* Vol. 1: Pages 1-16.
- Mascarenhas A., (2019) Explained: What's at stake in India's biggest ever trial of tuberculosis vaccines, *The Indian Express*, <https://indianexpress.com/article/explained/explained-whats-at-stake-in-indias-biggest-ever-trial-of-tuberculosis-vaccines-5867729/>
- Mathur H., Field D., Rea M. C., Cotter P. D., Hill C. and Ross R. P. (2018) Fighting biofilms with lantibiotics and other groups of bacteriocins. *NPJ Biofilms Microb*. Vol. 4 No.1
- Morisset D. and Frère J. (2002) Heterologous expression of bacteriocins using the mesentericin Y105 dedicated transport system by *Leuconostoc mesenteroides*. *Biochimie* Vol. 84 No.5–6: Pages 569–576.
- Mills S., Ross R. P. and Hill C. (2017) Bacteriocins and bacteriophage; a narrow-minded approach to food and gut microbiology. *FEMS Microbiology Reviews*. Vol. 41 Issue 1 : Pages S129–S153.
- Nagarajan D., Roy N., Kulkarni O., Nanajkar N., Datey A., Ravichandran S., Thakur C., Sandeep T., Aprameya I. V., Sarma S. P., Chakravorty D. and Chandra N. (2019) Ω 76: A designed antimicrobial peptide to combat carbapenem- and tigecycline-resistant *Acinetobacter baumannii*. *Sci. Adv*. Vol. 5: Pages 1 – 19.
- Nishie M., Nagao J. and Sonomoto K. (2012) Antibacterial peptides “bacteriocins”: An overview of their diverse characteristics and applications. *Biocontrol Sci*. Vol. 17 No. 1: Pages 1–16.
- Nitsch-Osuch A., Gyrczuk E., Wardyn A., Zycińska K. and Brydak L. (2016). Antibiotic prescription practices among children with influenza. *Adv. Exp. Med. Biol*. Vol. 905: Pages 25–31.
- Oldfield E. and Feng X. (2014) Resistance-resistant antibiotics. *Trends Pharmacol. Sci*. Vol. 35 No. 12 : Pages 664–674.
- Opsata M., Nes I. F. and Holo H. (2010) Class II bacteriocin resistance in *Enterococcus faecalis* V583: The mannose PTS operon mediates global transcriptional responses. *BMC Microbiology* Vol. 10: Page 224.
- O'Toole P. W. and Cooney J. C. (2008) Probiotic bacteria influence the composition and function of the intestinal microbiota. *Interdiscip. Perspect. Infect. Dis*.
- Papagianni M. and Anastasiadou S. (2009) Pediocins: the bacteriocins of *Pediococci*. Sources, production, properties and applications. *BioMed Central Microbial Cell Factor*. Vol. 8: Pages 3–19.
- Perez R. H., Zendo T., and Sonomoto K. (2018). Circular and leaderless bacteriocins: biosynthesis, mode of action, applications, and prospects. *Front. Microbiol*. 9:2085.
- Peng J., Long H., Liu W., Wu Z., Wang T., Zeng Z., Guo G. and Wu J. (2019) Antibacterial mechanism of peptide Cec4 against *Acinetobacter baumannii*. *Infection and Drug Resistance* Vol. 12: Pages 2417- 2428.
- Prakash V., Sreetha H., Poornima K. H., Lakshminol K. N., Regma R., Fathima H., Vishnu T. V., Venu S., Bipin G. Nair And Pal S. (2018) Antagonistic Effects Of Bacteriocins From *Lactobacillus* Spp. Against Enteric Pathogens. *Pollution Research Paper* Vol. 37: pages128-134.
- Martín-Escolano R., Cebrián R., Martín-Escolano J., Rosales M. J., Maquedab M., Sánchez-Moreno M. and Marina C. (2019) Insights into Chagas treatment based on the potential of bacteriocin AS-48. *IJP: Drugs and Drug Resistance* Vol. 10 Pages 1-8.
- Oldak A. and Zielinska D. (2017) Bacteriocins from lactic acid bacteria as an alternative to antibiotics. *Postepy Hig. Med. Dosw. (Online)* Vol. 71: Pages 328–338.
- Perales-Adán J., Rubiño S., Martínez-Bueno M., Valdivia E., Montalbán-López M., Cebrián R. and Maqueda M. (2018) LAB Bacteriocins Controlling the Food Isolated (Drug-Resistant) *Staphylococci*. *Frontiers in Microbiology* Vol. 9 Pages 1 -13.
- Rea M. C., Alemayehu D., Ross R. P. and Hill C. (2013) Gut solutions to a gut problem: Bacteriocins, probiotics and bacteriophage for control of *Clostridium difficile* infection. *J. Med. Microbiol*. Vol. 62 Pt 9: Pages 1369–1378.
- Santos V. L., Nardi R. M. D. and Dias-Souza M. V. (2017) Bacteriocins as Antimicrobial and Antibiofilm Agents. In book: *Current Developments in Biotechnology and Bioengineering*. Pages 403-436.
- Sachsenrödder J., Twardziok S. O., Scheuch M., John R. (2014). The general composition of the faecal virome of pigs

- depends on age, but not on feeding with a probiotic bacterium. *PLoS One* 9:e88888
- Sharma G., Dang S., Gupta S. and Gabrani R. (2018) Antibacterial Activity, Cytotoxicity, and the Mechanism of Action of Bacteriocin from *Bacillus subtilis* GAS101. *Med. Princ. Pract.* Vol. 27: Pages 186–192.
- Stepanauskas R., Glenn T. C., Jagoe C.H., Tuckfield R. C., Lindell A. H., King C. J. and McArthur J. V. (2006) Coselection for microbial resistance to metals and antibiotics in freshwater microcosms. *Environmental Microbiology* Vol. 8: Pages 1510 - 1514.
- Svetoch E. A., Eruslanov B. V., Levchuk V. P., Perelygin V. V., Mitsevich E. V., Mitsevich I. P., Stepanshin J., Dyatlov I., Seal B. S. and Stern N. J. (2011) Isolation of *Lactobacillus salivarius* 1077 (NRRL B-50053) and characterization of Its bacteriocin, including the antimicrobial activity spectrum. *Applied and Environmental Microbiology* Vol. 77 No. 8: Pages 2749–2754.
- Tashakor A., Hossein zadehdehkordi M., Emruzi Z. and Gholami D. (2017) Isolation and identification of a novel bacterium, *Lactobacillus sakei* subsp. dgh strain 5, and optimization of growth condition for highest antagonistic activity. *Microbial Pathogenesis*, Vol. 106: Pages 78–84.
- Turgis M., Vu K. D., Millette M., Dupont C. and Lacroix M. (2016) Influence of Environmental Factors on Bacteriocin Production by Human Isolates of *Lactococcus lactis* MM19 and *Pediococcus acidilactici* MM33. *Probiotics Antimicrob. Proteins* Vol. 8: Pages 53–59.
- Umu O. C. O., Rudi K. and Diep D. B. (2017) Modulation of the gut microbiota by prebiotic fibres and bacteriocins. *Microb. Ecol. Health Dis.* Vol. 28.
- Ventola C. L. (2015) The antibiotic resistance crisis: part 1: causes and threats. *P T* Vol. 40 No. 4: Pages 277–283.
- Vijayakumar, P. P. and Muriana, P. M. (2017) Inhibition of *Listeria monocytogenes* on ready-to-eat meats using bacteriocin mixtures based on mode-of-action. *Foods*. Vol. 6. No. 22.
- Viswanathan V. K. (2014) Off-label abuse of antibiotics by bacteria. *Gut Microbes* Vol. 5 No. 1: Pages 3–4.
- Weinstock G. M. (2016) A Glimpse of Microbial Power in Preventive Medicine. *JAMA Pediatr.* Vol. 170: Pages 11.
- WHO (2015). Antimicrobial Resistance, April 2015, Available online at www.who.int
- Weinstock G. M. (2016) A Glimpse of Microbial Power in Preventive Medicine. *JAMA Pediatr.* Vol. 170: Pages 11.
- Woraprayote W., Malila Y., Sorapukdee S., Swetwiwathana A., Benjakul S., and Visessanguan W. (2016). Bacteriocins from lactic acid bacteria and their applications in meat and meat products. *Meat Sci.* Vol. 120: Pages 118–132.
- Zheng J., Ganzle M.G., Lin X. B. Ruan L. and Sun M. (2015) Diversity and dynamics of bacteriocins from human microbiome. *Environ. Microbiol.* Vol. 17: Pages 2133–2143.